/24-7PressRelease/ - March 12, 2008 - After a short period of explosive growth that saw the market for drug eluting stents (DES) reach a peak of $5.1 billion within two years of the device launch in the US, the market experienced a correction.
Uncertainties regarding the risk of late stent thrombosis due to the use of the device led to a decline in the use of drug-eluting stents in percutaneous coronary intervention (PCI) procedures as well as a decline of total number of procedures performed, especially in the US.
According to a new report from Medtech Ventures, current market for drug eluting stents is estimated at $3.9 billion, accounting for 78% of total global coronary stents market. The US accounted for 46% of the global market followed by Europe accounting for 26% and Japan accounting for 12%.
Boston Scientific is the undisputed global market leader accounting for 46% of the market. The company is pursuing a dual drug strategy with the Taxus paclitaxel eluting stent and the Promus everolimus eluting stent.
Cordis, a Johnson & Johnson subsidiary, is the second leading player in the market accounting for 39% of the global DES market with its Cypher sirolimus eluting stent.
Medtronic came in third place with its Endeavor zotarolimus eluting stent and Abbott in forth place with its Xience everolimus eluting stent.
The sharp decline in the market for DES over the past year was due to a reduction in overall PCI procedures volume, reduction in DES penetration rate and defensive price cutting on behalf of marketing companies.
Early sings of stability in the number of PCI procedures performed in Cath Labs in the US and leveling of DES penetration rates as percentage of those procedures lead us to forecast a positive growth trend in the mid-single digit range for the market eventually leading to complete market recovery.
Drug Eluting Stents - Technology & Market Forecast is a New 2008 Edition of Medtech Ventures' best selling report. It provides a timely analysis of this market with profiles of leading participants and forecasts to the year 2015.
The report, which is targeted at busy senior executives in the medical device and venture capital industries, is now available for download from Medtech Reports website:
http://www.medtech-reports.com/drug-eluting-stents-market.htm
About Medtech Reports:
Medtech Reports aggregates strategy-level medical technology industry forecasting documents from a select group of consulting firms and market research publishers. For more information, visit http://www.Medtech-Reports.com.
Medtech Wire is a medical technology oriented news media publishing website. For more information, visit http://www.medtechwire.com.
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
- boston, cordis, device, drug, eluting, market, medical, medtech, medtronic, report, reports, research, scientific, stents, ventures
Read more Press Releases from Clyve Parker:Other Press Release Headlines:
